Boston Scientific

Boston Scientific’s Lotus™ Transcatheter Aortic Valve Implant has gained CE Mark approval as a treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.

Boston Scientific is never far from the news and this week is no exception as the company gains a prestigious award for its recently acquired subcutaneous ICD technology. At the same time news was released that its ongoing restructuring plans are likely to result in up to 1500 job losses.

Boston Scientific Corporation has completed enrollment in the EVOLVE II randomized, controlled clinical trial of its SYNERGY™Stent System. The safety and efficacy study will support U.S. FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.

Boston Scientific Corporation continues to expand its electrophysiology (EP) offerings with U.S. FDA approval of its IntellaTip MiFi™ XP catheter and 510(k) clearance of its Zurpaz™ 8.5F steerable sheath. The company says these products join its growing portfolio of next generation EP tools designed to redefine ablation technology.

Boston Scientific has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter trial evaluating the long-term (12 month) safety and effectiveness of its Innova™ Self-expanding Stent System.

Biomedical technology company SetPoint Medical,developing neuromodulation therapies for inflammatory diseases, has secured $27 million in financing from its current investors along with new investors who’s names you might recognise.

Boston Scientific Corporation has launched a clinical trial to determine whether occipital nerve stimulation using the company’s Precision™ System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.

Italy’s Sorin Group has issued a press release in which it confirms it will be participating in the manufacture of … continue reading “Sorin and Boston Scientific in TAVI Manufacturing Tie-up”

Boston Scientific Corporation has received U.S. FDA 510(k) clearance and CE Mark approval for the Guidezilla™ Guide Extension Catheter and … continue reading “FDA/CE Nod And Launch For Boston Sci’s Guidezilla™ Guide Extension Catheter”

Last month we covered the EU launch of Boston Scientific’s respiration-sensitive Vitalio™ pacemaker. Now the company has announced the first post-launch implantation of the device, which has taken place at a Dutch hospital.

C. R. Bard, Inc. has entered into an agreement to sell certain assets of its Electrophysiology division to Boston Scientific Corporation for $275 million in cash. The transaction is expected to close in 2013, subject to certain regulatory and customary closing conditions.

Boston Scientific Corporation is launching a new family of pacemakers in Europe, which monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

Boston Scientific Corporation is trumpeting a poster presentation at this week’s EHRA EuroPace 2013 in Athens. Data suggests the company’s … continue reading “Poster Points To Lower Complications For Boston’s S-ICD® System Vs Transvenous ICD Leads”

Another one of the renal denervation big boys sees data presented which confirms sustainable blood pressure reduction. This time its Boston Scientific, seeing clinical results using its recently acquired Vessix balloon-based system.

Boston Scientific Corporation has gained CE Mark approval for use of the GUIDE™ DBS System, the world’s first deep brain … continue reading “CE Mark For Boston Scientific’s GUIDE™ DBS System”

A first-in-human clinical trial using Boston Scientific’s IntellaTip MiFi™ XP Ablation Catheter for the treatment of type 1 atrial flutter has been completed in Australia.